MCID: END032
MIFTS: 32

Endometrial Clear Cell Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Endometrial Clear Cell Adenocarcinoma

MalaCards integrated aliases for Endometrial Clear Cell Adenocarcinoma:

Name: Endometrial Clear Cell Adenocarcinoma 12 15 17 74
Clear Cell Carcinoma of Endometrium 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5299
NCIt 51 C8028
UMLS 74 C0279765

Summaries for Endometrial Clear Cell Adenocarcinoma

Disease Ontology : 12 An endometrial adenocarcinoma that is characterized by the presence of cells with clear cytoplasm.

MalaCards based summary : Endometrial Clear Cell Adenocarcinoma, also known as clear cell carcinoma of endometrium, is related to adenocarcinoma and clear cell adenocarcinoma. An important gene associated with Endometrial Clear Cell Adenocarcinoma is CTSD (Cathepsin D), and among its related pathways/superpathways are Prolactin Signaling Pathway and Proteoglycans in cancer. The drugs Doxorubicin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, ovary and testes, and related phenotypes are digestive/alimentary and integument

Related Diseases for Endometrial Clear Cell Adenocarcinoma

Diseases related to Endometrial Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 40)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 10.2
2 clear cell adenocarcinoma 10.0
3 synchronous bilateral breast carcinoma 9.9 ESR1 TP53
4 female reproductive endometrioid cancer 9.9 ESR1 TP53
5 cervical carcinosarcoma 9.9 ESR1 TP53
6 glycogen-rich clear cell breast carcinoma 9.9 ESR1 TP53
7 adenosarcoma 9.9 ESR1 TP53
8 breast benign neoplasm 9.9 ESR1 TP53
9 thoracic benign neoplasm 9.9 ESR1 TP53
10 uterine corpus cancer 9.9 ESR1 TP53
11 hidradenocarcinoma 9.9 ESR1 TP53
12 pre-malignant neoplasm 9.9 ESR1 TP53
13 fallopian tube carcinoma 9.9 ESR1 TP53
14 in situ carcinoma 9.9 ESR1 TP53
15 breast carcinoma in situ 9.9 ESR1 TP53
16 malignant ovarian surface epithelial-stromal neoplasm 9.9 ESR1 TP53
17 ovary epithelial cancer 9.9 ESR1 TP53
18 female breast cancer 9.9 ESR1 TP53
19 larynx cancer 9.9 CTSD TP53
20 cervical adenocarcinoma 9.9 ESR1 TP53
21 estrogen-receptor positive breast cancer 9.8 ESR1 TP53
22 sweat gland cancer 9.8 ESR1 TP53
23 uterine anomalies 9.8 ESR1 TP53
24 sporadic breast cancer 9.8 ESR1 TP53
25 ductal carcinoma in situ 9.8 ESR1 TP53
26 female reproductive system disease 9.8 ESR1 TP53
27 reproductive system disease 9.8 ESR1 TP53
28 gonadal disease 9.8 ESR1 TP53
29 endometrial stromal sarcoma 9.8 ESR1 TP53
30 endocrine gland cancer 9.8 ESR1 TP53
31 meningioma, familial 9.7 ESR1 TP53
32 ovarian disease 9.7 ESR1 TP53
33 adamantinoma of long bones 9.6 ESR1 TP53
34 colonic disease 9.6 CTSD ESR1 TP53
35 endometrial adenocarcinoma 9.6 CTSD ESR1 TP53
36 breast ductal carcinoma 9.6 CTSD ESR1 TP53
37 breast adenocarcinoma 9.6 CTSD ESR1 TP53
38 breast disease 9.5 CTSD ESR1 TP53
39 wilms tumor 1 9.5 ESR1 TP53
40 endometrial cancer 9.5 CTSD ESR1 TP53

Graphical network of the top 20 diseases related to Endometrial Clear Cell Adenocarcinoma:



Diseases related to Endometrial Clear Cell Adenocarcinoma

Symptoms & Phenotypes for Endometrial Clear Cell Adenocarcinoma

MGI Mouse Phenotypes related to Endometrial Clear Cell Adenocarcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.13 CTSD ESR1 TP53
2 integument MP:0010771 8.8 CTSD ESR1 TP53

Drugs & Therapeutics for Endometrial Clear Cell Adenocarcinoma

Drugs for Endometrial Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
3
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
4
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1
5
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
6
Epirubicin Approved Phase 3 56420-45-2 41867
7
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
8
Pembrolizumab Approved Phase 3 1374853-91-4
9
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
10 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
11 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
12 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
13 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
14 Antimitotic Agents Phase 3,Phase 2,Phase 1
15 Adjuvants, Immunologic Phase 3,Phase 1
16 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
17 Immunologic Factors Phase 3,Phase 2,Phase 1
18 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
19 Hypoglycemic Agents Phase 2, Phase 3
20
Sodium Citrate Approved, Investigational Phase 2 68-04-2
21
Gemcitabine Approved Phase 2 95058-81-4 60750
22
Nintedanib Approved Phase 2 656247-17-5 56843413
23
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
24
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
25
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 5284616 6436030
26
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
27
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
28
Dasatinib Approved, Investigational Phase 2,Phase 1 302962-49-8 3062316
29
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
30
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
31
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
32
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
33
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
34
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
35
Cediranib Investigational Phase 2 288383-20-0 9933475
36
Trebananib Investigational Phase 2 894356-79-7
37 Calcium, Dietary Phase 2
38 Citrate Phase 2
39 Chelating Agents Phase 2
40 Anticoagulants Phase 2
41 Immunosuppressive Agents Phase 2
42 Antimetabolites Phase 2
43 Antiviral Agents Phase 2,Phase 1
44 Anti-Infective Agents Phase 2,Phase 1
45 Antimetabolites, Antineoplastic Phase 2
46 Protein Kinase Inhibitors Phase 2,Phase 1
47 Immunoglobulins Phase 2,Phase 1
48 Immunoglobulin Fc Fragments Phase 2
49 Antibodies Phase 2,Phase 1
50 Mitogens Phase 2,Phase 1

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
2 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
3 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
4 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
5 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
6 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
7 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
8 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
9 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
10 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
11 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
12 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
13 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
14 Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Not yet recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
15 Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer Unknown status NCT01100359 Phase 2 carboplatin;liposome-encapsulated doxorubicin citrate
16 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01011933 Phase 2 Selumetinib
17 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
18 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
19 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
20 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
21 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
22 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
23 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
24 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
25 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
26 S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
27 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
28 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
29 Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
30 Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Recruiting NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
31 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
32 Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Recruiting NCT00492778 Phase 2 Cisplatin
33 Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Active, not recruiting NCT02059265 Phase 2 Dasatinib
34 Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT01935934 Phase 2 Cabozantinib S-malate
35 Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2 Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
36 Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer Not yet recruiting NCT03836157 Phase 2 Mirvetuximab Soravtansine;Bevacizumab
37 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005840 Phase 1 Paclitaxel;Cisplatin
38 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005830 Phase 1 Doxorubicin Hydrochloride;Cisplatin
39 Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Completed NCT01440998 Phase 1 Carboplatin;Dasatinib;Paclitaxel
40 Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer Completed NCT00575952 Phase 1 Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
41 Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery Completed NCT00448643 Phase 1 Cisplatin
42 Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Active, not recruiting NCT01935973 Phase 1 Trametinib;Uprosertib
43 TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Active, not recruiting NCT02142803 Phase 1 Sapanisertib
44 VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Suspended NCT03120624 Phase 1 Technetium Tc-99m Sodium Pertechnetate
45 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
46 Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer Unknown status NCT01150682
47 PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer Active, not recruiting NCT01737619 Not Applicable Indocyanine Green Solution

Search NIH Clinical Center for Endometrial Clear Cell Adenocarcinoma

Genetic Tests for Endometrial Clear Cell Adenocarcinoma

Anatomical Context for Endometrial Clear Cell Adenocarcinoma

MalaCards organs/tissues related to Endometrial Clear Cell Adenocarcinoma:

42
Lymph Node, Ovary, Testes, Endothelial, Colon, Bone

Publications for Endometrial Clear Cell Adenocarcinoma

Articles related to Endometrial Clear Cell Adenocarcinoma:

# Title Authors Year
1
Endometrial clear cell adenocarcinoma diagnosed by endometrial cytological examination: two cases report. ( 21319323 )
2011

Variations for Endometrial Clear Cell Adenocarcinoma

Cosmic variations for Endometrial Clear Cell Adenocarcinoma:

9 (show top 50) (show all 399)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6845145 ZFHX3 endometrium,NS,carcinoma,clear cell carcinoma c.8617G>A p.E2873K 16:72794065-72794065 0
2 COSM6980835 YAP1 endometrium,NS,carcinoma,clear cell carcinoma c.451C>G p.P151A 11:102114273-102114273 0
3 COSM6928566 XPO1 endometrium,NS,carcinoma,clear cell carcinoma c.1888G>A p.V630I 2:61490776-61490776 0
4 COSM6980818 VTCN1 endometrium,NS,carcinoma,clear cell carcinoma c.38T>A p.I13N 1:117170166-117170166 0
5 COSM6949653 VEGFA endometrium,NS,carcinoma,clear cell carcinoma c.547T>C p.F183L 6:43771253-43771253 0
6 COSM6949674 TSC2 endometrium,NS,carcinoma,clear cell carcinoma c.3870C>A p.S1290R 16:2082491-2082491 0
7 COSM6962389 TSC2 endometrium,NS,carcinoma,clear cell carcinoma c.1790A>G p.H597R 16:2070529-2070529 0
8 COSM6904337 TSC1 endometrium,NS,carcinoma,adenocarcinoma c.2698C>G p.Q900E 9:132897538-132897538 0
9 COSM10662 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 0
10 COSM6932 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.733G>A p.G245S 17:7674230-7674230 0
11 COSM10648 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.524G>A p.R175H 17:7675088-7675088 0
12 COSM10709 TP53 endometrium,NS,carcinoma,adenocarcinoma c.722C>G p.S241C 17:7674241-7674241 0
13 COSM44063 TP53 endometrium,NS,carcinoma,adenocarcinoma c.389T>G p.L130R 17:7675223-7675223 0
14 COSM10704 TP53 endometrium,NS,carcinoma,adenocarcinoma c.844C>T p.R282W 17:7673776-7673776 0
15 COSM43708 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.422G>A p.C141Y 17:7675190-7675190 0
16 COSM11073 TP53 endometrium,NS,carcinoma,adenocarcinoma c.1024C>T p.R342* 17:7670685-7670685 0
17 COSM11063 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.711G>T p.M237I 17:7674252-7674252 0
18 COSM10663 TP53 endometrium,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 0
19 COSM10660 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.818G>A p.R273H 17:7673802-7673802 0
20 COSM44175 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.644G>C p.S215T 17:7674887-7674887 0
21 COSM44622 TP53 endometrium,NS,carcinoma,adenocarcinoma c.694A>G p.I232V 17:7674269-7674269 0
22 COSM10659 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.817C>T p.R273C 17:7673803-7673803 0
23 COSM10654 TP53 endometrium,NS,carcinoma,adenocarcinoma c.637C>T p.R213* 17:7674894-7674894 0
24 COSM45035 TP53 endometrium,NS,carcinoma,adenocarcinoma c.761T>G p.I254S 17:7674202-7674202 0
25 COSM43906 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.843C>A p.D281E 17:7673777-7673777 0
26 COSM4429613 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.343C>T p.H115Y 17:7676026-7676026 0
27 COSM10808 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.488A>G p.Y163C 17:7675124-7675124 0
28 COSM44630 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.332T>A p.L111Q 17:7676037-7676037 0
29 COSM43545 TP53 endometrium,NS,carcinoma,adenocarcinoma c.503A>G p.H168R 17:7675109-7675109 0
30 COSM10733 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.574C>T p.Q192* 17:7674957-7674957 0
31 COSM43901 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.421T>C p.C141R 17:7675191-7675191 0
32 COSM11287 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.839G>T p.R280I 17:7673781-7673781 0
33 COSM10758 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.659A>G p.Y220C 17:7674872-7674872 0
34 COSM10742 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.578A>G p.H193R 17:7674953-7674953 0
35 COSM43905 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.590T>G p.V197G 17:7674941-7674941 0
36 COSM10656 TP53 endometrium,NS,carcinoma,adenocarcinoma c.742C>T p.R248W 17:7674221-7674221 0
37 COSM43596 TP53 endometrium,NS,carcinoma,adenocarcinoma c.841G>A p.D281N 17:7673779-7673779 0
38 COSM44226 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.380C>T p.S127F 17:7675232-7675232 0
39 COSM44240 TP53 endometrium,NS,carcinoma,clear cell carcinoma c.514G>T p.V172F 17:7675098-7675098 0
40 COSM1635939 TGFBR1 endometrium,NS,carcinoma,clear cell carcinoma c.1460G>A p.R487Q 9:99149253-99149253 0
41 COSM43420 TET2 endometrium,NS,carcinoma,clear cell carcinoma c.4546C>T p.R1516* 4:105275056-105275056 0
42 COSM6980832 TCF7L2 endometrium,NS,carcinoma,clear cell carcinoma c.1555C>A p.P519T 10:113165736-113165736 0
43 COSM1177847 SPOP endometrium,NS,carcinoma,clear cell carcinoma c.240C>G p.S80R 17:49619346-49619346 0
44 COSM980812 SPOP endometrium,NS,carcinoma,clear cell carcinoma c.349A>G p.M117V 17:49619237-49619237 0
45 COSM980811 SPOP endometrium,NS,carcinoma,clear cell carcinoma c.362G>A p.R121Q 17:49619099-49619099 0
46 COSM6904351 SPOP endometrium,NS,carcinoma,clear cell carcinoma c.235G>A p.E79K 17:49619351-49619351 0
47 COSM5414953 SPOP endometrium,NS,carcinoma,clear cell carcinoma c.355A>G p.S119G 17:49619106-49619106 0
48 COSM4268419 SPOP endometrium,NS,carcinoma,clear cell carcinoma c.351G>A p.M117I 17:49619235-49619235 0
49 COSM5414954 SPOP endometrium,NS,carcinoma,clear cell carcinoma c.351G>T p.M117I 17:49619235-49619235 0
50 COSM6904350 SPOP endometrium,NS,carcinoma,clear cell carcinoma c.229G>T p.D77Y 17:49619357-49619357 0

Expression for Endometrial Clear Cell Adenocarcinoma

Search GEO for disease gene expression data for Endometrial Clear Cell Adenocarcinoma.

Pathways for Endometrial Clear Cell Adenocarcinoma

Pathways related to Endometrial Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.91 CTSD ESR1
2 11.74 ESR1 TP53
3 11.59 ESR1 TP53
4 11.49 CTSD TP53
5 11.4 CTSD TP53
6 11.32 ESR1 TP53
7 10.72 ESR1 TP53
8 10.5 ESR1 TP53
9 10.42 CTSD ESR1 TP53

GO Terms for Endometrial Clear Cell Adenocarcinoma

Cellular components related to Endometrial Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 8.62 ESR1 TP53

Biological processes related to Endometrial Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.16 ESR1 TP53
2 protein deubiquitination GO:0016579 8.96 ESR1 TP53
3 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 8.62 ESR1 TP53

Sources for Endometrial Clear Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....